| Literature DB >> 21251825 |
Daniel V Paone1, Diem N Nguyen, Anthony W Shaw, Christopher S Burgey, Craig M Potteiger, James Z Deng, Scott D Mosser, Christopher A Salvatore, Sean Yu, Shane Roller, Stefanie A Kane, Harold G Selnick, Joseph P Vacca, Theresa M Williams.
Abstract
In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacements and SAR of the imidazole yielded the tertiary methyl ether as an optimal substituent for potency and hERG selectivity. Combination with the azabenzoxazinone spiropiperidine ultimately led to preclinical candidate 30 (MK-2918).Entities:
Mesh：
Substances：
Year: 2010 PMID： 21251825 DOI： 10.1016/j.bmcl.2010.12.054
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823